May 23, 2018 04:21 PM IST
Centrum is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 930 in its research report dated May 16, 2018.
May 23, 2018 03:25 PM IST
Motilal Oswal is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 865 in its research report dated May 15, 2018.
May 21, 2018 05:47 PM IST
KR Choksey recommended hold rating on Lupin with a target price of Rs 785 in its research report dated May 17, 2018.
May 16, 2018 02:22 PM IST
India’s second-largest drug maker on Tuesday posted a massive net loss of Rs 783.5 crore in the fourth quarter ended March due to a one-time impairment provision on certain made on certain intangible assets related to Gavis acquisition in US.
May 15, 2018 03:21 PM IST
The company reported a net profit of Rs 383.6 crore in the period previous year ago. The sales fell 2.8 percent to Rs 4179 crore.
May 14, 2018 09:51 PM IST
A Reuters poll of equity analysts estimated the net profit to rise to Rs 323.8 crore.
May 14, 2018 12:06 PM IST
Nagpur facility is the company's latest facility and manufactures oral solid products.
May 14, 2018 10:31 AM IST
In a BSE filing, Lupin "announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations".
May 10, 2018 06:37 PM IST
Corcal Bone and Beauty has been introduced under the company’s consumer healthcare division, Lupin Ltd said in a statement.
May 08, 2018 05:50 PM IST
Lupin said the filing also opens up other key markets like Europe, Canada, Australia, the Middle East, South East Asia and Latin America for this product within the next 12 to 18 months
May 07, 2018 04:55 PM IST
The company has received final approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Fougera Pharmaceuticals Inc's Temovate ointment, Lupin Ltd said in a statement.
May 07, 2018 12:21 PM IST
The market breadth was in favour of the advances with 954 stocks advancing while 724 declined and 378 remained unchanged. On the other hand, in the BSE, 1279 stocks advanced and 1140 declined and 107 remained unchanged.
April 23, 2018 03:14 PM IST
Net Sales are expected to decrease by 3 percent Y-o-Y (up 3.5 percent Q-o-Q) to Rs. 4,037.9 crore, according to KR Choksey.
April 23, 2018 02:27 PM IST
Tetrabenazine tablets is a generic version of Valeant Pharmaceuticals North America, LLC's Xenazine tablets, 12.5 mg and 25 mg.
April 20, 2018 12:55 PM IST
Net Sales are expected to decrease by 10.6 percent Y-o-Y (down 4.4 percent Q-o-Q) to Rs. 3,800 crore, according to HDFC Securities.
April 16, 2018 06:21 PM IST
Net Sales are expected to decrease by 8.4 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,895.1 crore, according to Edelweiss.
April 03, 2018 11:31 AM IST
Pharma major Lupin today said the UK health regulator has completed inspection of its Goa facility without making any critical observations.
April 02, 2018 12:18 PM IST
The market breadth was in favour of the advances with 1432 stocks advancing while 306 declined and 314 remained unchanged. On the other hand, in the BSE, 1997 stocks advanced and 546 declined and 130 remained unchanged.
April 02, 2018 10:55 AM IST
"Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'," Lupin said in a BSE filing.
March 27, 2018 03:56 PM IST
Lupin's product is a generic version of Galderma Laboratories LP's Clobex, which is indicated for treatment of moderate to severe plaque psoriasis.
March 26, 2018 02:25 PM IST
The company has launched the product in the strength of 25 mg after approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
March 22, 2018 10:47 AM IST
The market breadth was in favour of the declines with 706 stocks advancing while 902 declined and 407 remained unchanged. On the other hand, in the BSE, 984 stocks advanced and 1126 declined and 135 remained unchanged.
March 19, 2018 01:09 PM IST
Drug major Lupin today said it has received approval from the US health regulator to market Desoximetasone Topical spray, used for treatment of plaque psoriasis, in the American market.
March 07, 2018 10:27 AM IST
The market breadth was in favour of the declines with 428 stocks advancing while 1215 declined and 367 remained unchanged. On the other hand, in the BSE, 645 stocks advanced and 1542 declined and 94 remained unchanged.
February 26, 2018 04:17 PM IST
Mitessh Thakkar of miteshthacker.com recommends buying Bharat Electronics, Tata Motors, Lupin and L&T Finance Holdings.
